Company Encyclopedia
View More
name
Aurinia Pharma
AUPH.US
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases.
1.946 T
AUPH.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking28/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE20.65%A
    • Profit Margin29.28%A
    • Gross Margin88.42%A
  • Growth ScoreB
    • Revenue YoY20.62%B
    • Net Profit YoY445.14%A
    • Total Assets YoY-3.97%D
    • Net Assets YoY-5.73%D
  • Cash ScoreB
    • Cash Flow Margin341.49%C
    • OCF YoY20.62%B
  • Operating ScoreC
    • Turnover0.49C
  • Debt ScoreB
    • Gearing Ratio30.66%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aurinia Pharmaceuticals Inc $AUPH Stake Trimmed by Geode Capital Management LLC

    Geode Capital Management LLC reduced its stake in Aurinia Pharmaceuticals Inc by 9.1% during Q2, owning 1,577,060 shares worth $13.35 million. Other hedge funds have also adjusted their positions in AUPH. Analysts have mixed ratings on the stock, with a consensus 'Hold' rating and a target price of $17.67. Aurinia's Q3 earnings beat estimates, reporting $0.23 EPS and $73.47 million revenue.

    Market Beat·
    US
    AUPH
    +2.68%
    Market Beat·
    US
    AUPH
    +2.68%

    Dir Johnson Surrenders 6,039 Of Aurinia Pharmaceuticals Inc [AUPH]

    Director Johnson Craig A of Aurinia Pharmaceuticals Inc surrendered 6,039 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on November 24, 2025. The transaction was valued at $94,692, with shares priced at $15.68 each. Johnson's ending holdings are 14,592 shares directly.

    Reuters·
    US
    AUPH
    +2.68%
    Reuters·
    US
    AUPH
    +2.68%

    Aurinia Pharmaceuticals (NasdaqGM:AUPH): Does Upgraded 2025 Revenue Guidance Signal a Shift in Valuation?

    Aurinia Pharmaceuticals (AUPH) has upgraded its 2025 revenue guidance and reported stronger quarterly results, leading to increased investor interest. The stock's year-to-date return is up 76.6%, with a one-year return of 93.4%. Despite this, the stock is considered overvalued with a fair value of $13 compared to the last close price of $15.49. However, a DCF model suggests it is undervalued with a fair value of $34.89. Operational efficiency improvements and strategic restructuring are expected to enhance margins. Investors are evaluating whether future growth is already priced in.

    Simplywall·
    US
    AUPH
    +2.68%
    Simplywall·
    US
    AUPH
    +2.68%

    Jupiter Asset Management Ltd. Buys 181,093 Shares of Aurinia Pharmaceuticals Inc $AUPH

    Jupiter Asset Management Ltd. increased its stake in Aurinia Pharmaceuticals by 24.1% in Q2, owning 933,862 shares worth $7.91 million. Analysts have mixed ratings on AUPH, with a consensus "Hold" and target price of $17.67. The stock opened at $15.22, with a market cap of $2.01 billion. Aurinia reported Q3 EPS of $0.23, beating estimates, and revenue of $73.47 million. The company focuses on therapies for unmet medical needs, offering LUPKYNIS for lupus nephritis.

    Market Beat·
    US
    AUPH
    +2.68%
    Market Beat·
    US
    AUPH
    +2.68%

    Aurinia Pharmaceuticals (NasdaqGM:AUPH): Valuation Insights Following Strong Q3 Results and Raised 2025 Guidance

    Aurinia Pharmaceuticals (AUPH) reported strong Q3 results and raised its 2025 guidance, boosting investor confidence. The stock saw a 13% increase over seven days and a 32% rise in the past month, with a year-to-date gain of nearly 70%. However, analysts debate its valuation, with some viewing it as overvalued at a fair value of $13, while others, using a DCF model, suggest it is undervalued by 57.2%. Investors are advised to remain vigilant due to reliance on Lupkynis and global drug pricing pressures.

    Simplywall·
    US
    AUPH
    +2.68%
    Simplywall·
    US
    AUPH
    +2.68%
    © 2025 Longbridge｜Disclaimer